May 9th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Overcoming Resistance to Agents Treating BRAF Mutations in Colorectal Cancer
November 28th 2019Precision and personalized medicine targeting driver mutations has revolutionized cancer care in the past decade. Targeted therapy has entered the world of colorectal cancer research with the identification of mutations in KRAS and BRAF genes.
Read More
Resistance Mutations Pose Complex Challenges for Pathologists
November 13th 2019The emergence of resistance mutations in patients with cancer who receive targeted therapies is an expected development that will require new diagnostic methods of identifying the mechanisms through which these alterations occur, according to Fei Dong, MD, during the 2019 Association for Molecular Pathology Annual Meeting.<br />
Read More
Differences in Prognoses for Patients With Right-Sided or Left-Sided Colorectal Cancer
October 25th 2019Scott Kopetz, MD, PhD, explains how prognoses for patients with colorectal cancer differ based on whether their cancer is left-sided or right-sided and discusses how knowledge of these differences have led to the development of more agents to treat both groups of patients.
Watch
Onvansertib Show Early Signals of Safety and Efficacy in KRAS-Mutated mCRC
October 23rd 2019The combination of onvansertib, a third-generation adenosine triphosphate inhibitor, with FOLFIRI and bevacizumab achieved positive responses in patients with metastatic colorectal cancer in the second-line setting, according to the results of a phase Ib/II reported in a press release from Trovagene, Inc.<br />
Read More
FDA Approves New Aprepitant Dosing Regimen for CINV After MEC
October 23rd 2019The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Read More
Combinations With PD-1/PD-L1 Agents May Improve Outcomes in mCRC, Studies Show
October 15th 2019In an interview with Targeted Oncology, Tanios Bekaii-Saab, MD, discussed the results of the BACCI and MOUNTAINEER studies, which showed promise for the use of PD-1/PD-L1 combinations over single-agent treatment in patients with metastatic colorectal cancer.
Read More
Targeted Agents May Be Moving Closer to Frontline for Treatment of mCRC
October 14th 2019Treatment targeting molecular pathways such as <em>BRAF, </em>HER2<em>,</em> and <em>RAS</em> has typically been reserved for later lines of therapy for patients with metastatic colorectal cancer. Benjamin A. Weinberg, MD, said that agents targeting these pathways are not yet ready for the upfront setting, but data from ongoing trials suggest that these agents may eventually have a role to play in first- and second-line treatment.
Read More
Immunotherapy Options Growing for Metastatic Colorectal Cancer
October 14th 2019Immunotherapeutic agents have grown in popularity for treating mismatch repair–deficient metastatic colorectal cancer, becoming the standard of care in the second line, Howard Hochster, MD, told an audience at the 2019 Gastrointestinal Oncology Conference. Furthermore, ongoing clinical trials suggest that these agents may play a larger role in treating CRC going forward.
Read More
Case Series Reveals Activity of Afatinib in NRG1+ Solid Tumors
October 11th 2019In a presentation at the 2019 ESMO Congress on a case series of 7 pretreated patients with <em>NRG1</em>-positive tumors, Stephen Liu, MD, and colleagues discussed the efficacy of afatinib and explained that afatinib may be a potential treatment option for <em>NRG1</em>-positive tumors across multiple cancer types.
Read More
Kasi Analyzes Role of Liquid Biopsies in CRC Ahead of 2019 ISGIO Annual Conference
October 9th 2019In an interview with <em>Targeted Oncology</em>, Kasi, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at the University of Iowa, Holden Comprehensive Cancer Center, discussed the current role and utility of liquid biopsy in colorectal cancer, and what he’s looking forward to bringing up during the 2019 ISGIO Annual Conference.
Read More
ASCO Adds Oral Anticoagulants to Venous Thromboembolism Guidelines for Patients With Cancer
October 4th 2019The addition of direct oral oral anticoagulants for the management of venous thromboembolism in patients with cancer is the latest change to previous guidelines issued by the American Society of Clinical Oncology.
Read More
Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib
October 3rd 2019Using a measure known as the growth modulation index, patients with TRK fusion–positive cancers who were treated with larotrectinib had a clinically meaningful improvement in progression-free survival compared with the time to progression on their prior treatment, an analysis of patients enrolled in 1 of 3 clinical trials has found.
Read More
Larotrectinib Maintains Safety and High Efficacy in TRK Fusion-Positive Cancer
September 29th 2019Three clinical trials presented at the 2019 ESMO Congress show that the tropomyosin receptor kinase inhibitor larotrectinib continues to show anti-tumor activity, including long-lasting objective responses and low toxicity, according to results from an integrated analysis.
Read More
Identification of Actionable Mutations Remains an Unmet Need in CRC
September 26th 2019Gulam A. Manji, MD, PhD, discusses the need to identify mutations that may be actionable in patients with colorectal cancer. The identification of such mutations can further impact patient survival and improve efficacy, says Manji, in both CRC and other gastrointestinal cancers.
Watch
FDA Expands Indication for CRC Screening Test to Include Younger Patients
September 24th 2019The FDA has expanded the indication for the Cologuard noninvasive screening test for colorectal cancer to include eligible patients with an average risk of developing colorectal cancer who are between the ages of 45 and 49.
Read More
Stein Reviews the Latest Advancements in the Treatment of CRC to be Discussed at ISGIO
September 23rd 2019In an interview with Targeted Oncology, Stacey Stein, MD, discussed what attendees can expect to learn about at the 2019 ISGIO Annual Conference in terms of the treatment landscape for CRC. She also highlighted some of the recent advancements that physicians treating CRC should be aware of heading into this meeting.
Read More
Patients With BRAF+ non-V600 Colorectal Cancer May Be Sensitive to Anti-EGFR Therapy
September 21st 2019Certain patients with BRAF non-V600-mutant, RAS-dependent metastatic colorectal cancer may be sensitive to anti-EGFR therapy, according to the results of a a multicenter pooled analysis recently published in Clinical Cancer Research. The analysis suggested that those with RAS<em>-</em>dependent tumors were more likely to respond to anti-EGFR therapy than those with RAS-independent tumors.
Read More
Grothey Emphasizes Multidrug Therapies in mCRC
September 17th 2019The use of more aggressive frontline chemotherapy regimens plus biologics for the treatment of patients with meta-static colorectal cancer may be warranted based on mutational status, tumor sidedness, treatment goals, prognosis, and patient disposition, according to a presentation by Axel Grothey, MD, at the 14th Annual New Orleans Summer Cancer Meeting, held July 19 to 21, 2019, in Louisiana.
Read More
Nivolumab/Ipilimumab Combination Data Promising in MSI-H/dMMR mCRC
August 27th 2019Heinz-Josef Lenz, MD, discusses the significance of the latest updates in the CheckMate 142 trial exploring an immunotherapy treatment combination in patients with metastatic colorectal cancer whose tumors are microsatellite instability–high or mismatch repair deficient.
Watch
Marshall Examines TKIs and Immunotherapy Agents for GI Cancers
August 24th 2019John L. Marshall, MD, spoke with a group of physicians during a Targeted Oncology live case-based peer perspectives discussion on the different classes of agents available to treat patients with gastrointestinal cancers.
Read More
Manji Advises on Community Oncologists Targeting Molecular Markers in Patients with Colon Cancer
August 19th 2019In an interview with <em>Targeted Oncology</em> following his presentation at the <em>3rd Annual</em> Congress on Oncology & Pathology hosted by PER®, Gulam A. Manji, MD, discussed the emergence of new therapies for targeting mutations in patients with colon cancer.
Read More
Raghav Works Through a CRC Patient Case After First-and Second-Line Therapy Exhaustion
August 17th 2019At a recent Targeted Oncology live case-based peer perspectives event, Kanwal P. S. Raghav, MBBS, MD, presented a case scenario of a patient with colorectal cancer who has already gone through first- and second-line treatments. Raghav explained the treatment considerations he would make with similar patients in the clinic and the treatment options available to this patient with CRC in this setting.
Read More
OS Endpoint Not Met in Pivotal Phase III CRC IMPALA Trial
August 9th 2019Overall survival was not improved with the use of lefitolimod as a maintenance therapy compared with local standard-of-care therapy in patients with metastatic colorectal cancer, according to early findings from the pivotal phase III IMPALA trial. The median OS was 22.0 months with lefitolimod compared with 21.9 months with standard of care, which failed to meet the primary endpoint of the trial.
Read More
Regorafenib/Nivolumab Combo to Be Studied in Phase III Trial of Patients With MSS mCRC
July 19th 2019A phase III trial is being initiated to evaluate the combination of regorafenib and nivolumab in comparison with regorafenib alone in patients with microsatellite stable metastatic colorectal cancer.
Read More
Dose-Optimization Strategies Continue for Regorafenib in Colorectal Cancer With ReDOS Success
July 17th 2019A dose-escalation strategy for giving regorafenib improved the frequency of adverse events while still demonstrating similar efficacy to a standard-dose strategy in patients with metastatic colorectal cancer.
Read More